Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

WellDoc Announces Providence Health & Services’ Implementation of BlueStar® Digital Therapeutic in a Pilot Program for Individuals with Type 2 Diabetes


Posted on: 03 Apr 18

COLUMBIA, Md., April 03, 2018 (GLOBE NEWSWIRE) -- Today, WellDoc® announced a pilot program in the Providence Health & Services Oregon/SW Washington Region to examine the use of WellDoc’s BlueStar®, an FDA-cleared, proven digital therapeutic for individuals with type 2 diabetes. The Providence Health & Services pilot program will include individuals living with type 2 diabetes and will evaluate the impact of a digital therapeutic—when used in conjunction with the support of a dedicated Diabetes Educator—on user engagement, retention, satisfaction and clinical outcomes.

“We’re pleased to announce this pilot program with Providence Health & Services,” said WellDoc President and CEO Kevin McRaith. “We expect great outcomes from this initial engagement and look forward to expanding our partnership to scale to meet the needs of all Providence patients living with type 2 diabetes.”

BlueStar provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal for individuals living with type 2 diabetes. Clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar. BlueStar harnesses evidence-based diabetes management, behavior management, and user experience to engage and provide individualized guidance when needed to people with type 2 diabetes. It provides this within a scalable self-management platform built on adaptive in-app coaching and actionable patient-generated health data. This platform is designed to connect adults living with type 2 diabetes, their health care team members, and payers through enhanced communication and support – resulting in proven clinical outcomes and cost savings.

About BlueStar®

BlueStar®, powered by WellDoc®, is an FDA-cleared, proven digital therapeutic that is an in-app coach engaging people with type 2 diabetes. It delivers personalized, real-time feedback, as well as diabetes educational tools that are actionable and individualized. Specifically, WellDoc has developed more than 30 peer-reviewed publications and presentations on BlueStar, including two randomized, controlled clinical trials. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes treatment. BlueStar delivers an estimated average cost savings of $254-$271 per user per month, proven clinical outcomes and a net promoter member satisfaction score of 70. For more information on BlueStar, visit: www2.bluestardiabetes.com.

This year, Samsung Electronics America, Inc. and WellDoc announced that Samsung Health users now have access to a new consumer version of WellDoc’s digital platform known as the Diabetes Wellness Program (DWP). The DWP, which is integrated within the Samsung Health service, is a 12-week health and wellness program designed to help adults with type 2 diabetes achieve a healthy lifestyle and to help manage their condition. More information on DWP is available at: www.welldoc.com/diabeteswellness

About WellDoc®

WellDoc® is a leading digital therapeutic company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of helping individuals self-manage their conditions to achieve significant clinical outcomes and cost savings. We began our journey by mastering diabetes management solutions and are moving rapidly into creating additional tools for managing other chronic diseases including hypertension, chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have taken an aggressive and innovative approach that utilizes sophisticated logic, precise algorithms, and artificial intelligence (AI), which integrates the most advanced mobile technology and behavioral insights. WellDoc partners with, collaborates with, and is backed by top healthcare companies (including Merck and Johnson and Johnson), leading innovators, dedicated investors, and top mobile technology companies (such as Samsung). For more information, visit www.welldoc.com.

Media Contact:
Juliette Bogus
PressComm PR for WellDoc
Email: juliettebogus@presscommpr.com
Tel: +410.980.5687

GlobeNewswire
globenewswire.com

Last updated on: 04/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.